Harmony Biosciences (HRMY) Q2 2026 Earnings Call Transcript
Harmony Biosciences (HRMY) reported Q2 2026 WAKIX net revenue of $261.3 million, up 30% year over year, and confirmed 2026 revenue guidance of $1.0 billion to $1.04 billion. Net income was $75.4 million ($1.28/diluted share). Cash and investments were $962.5 million as of June 30, 2026. The company also discussed BP-205 clinical data and pipeline timelines.
How this was made
The 30-second read
Why it matters
Traders can update models for 2026 revenue expectations using the confirmed guidance and Q2 datapoints, while also repricing probability-weighted timelines for multiple clinical readouts and FDA milestones (including pitolisant GR PDUFA April 1, 2027).
Market read
Record WAKIX revenue and confirmed 2026 guidance are the main positive catalysts, while pipeline timing delays and early BP-205 mechanistic AEs are key risk items for valuation and trading into future readouts.
What to watch
Cost of product sold rose to 24.2% of revenue (from 19%), attributed to new Novitium royalties, which may pressure gross margin even as top-line grows.
Background
This is a transcript-style summary of Harmony Biosciences’ Q2 2026 earnings call, covering WAKIX commercial performance, financial position, and pipeline updates for BP-205 and pitolisant-related programs.
Ticker impact
Harmony reported Q2 2026 WAKIX net revenue of $261.3M (+30% YoY) and confirmed 2026 revenue guidance of $1.0B to $1.04B.
Near-term bias likely positive if investors focus on confirmed revenue guidance and record WAKIX revenue, but volatility risk remains from clinical timeline delays and safety signals in BP-205 early studies.
The article includes multiple new quantitative datapoints (revenue, net income, cash/debt) plus updated clinical and regulatory milestones (PDUFA dates, top-line timing delays). These are typically material for biotech valuation and near-term positioning.
Market effects
Reinforces investor appetite for commercial-stage rare-disease neurology franchises with expanding field coverage and durable payer coverage.
Limited direct regional spillover; primarily US biotech sentiment and FDA milestone expectations.
Modest global relevance, driven by FDA timeline signaling and pipeline progress rather than cross-border regulatory actions.
Counterpoint
The confirmed revenue range may already be priced in, and the call highlights delays (TEMPO top-line mid-2027, EPX-100 mid-2027) plus BP-205 target engagement AEs, which could temper enthusiasm.
Key entities
- companyHarmony Biosciences Holdings, Inc.
Subject of the earnings call transcript, reporting Q2 2026 results and providing guidance and pipeline timelines.
- productWAKIX
Narcolepsy therapy discussed with record quarterly revenue, patient counts, and payer coverage.
- clinical programBP-205
Lead orexin-2 agonist with updated pharmacokinetics and early safety observations, plus planned Phase Ib initiation in Q3 2026.
- regulatory milestonePitolisant GR
Gastro-resistant formulation with a stated PDUFA date of April 1, 2027.
- legal matterAET
Named in litigation context, with closing arguments requested for Oct. 22, 2026.
